Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion has begun an underwritten equity and pre-funded warrant offering under an effective shelf registration, with final terms still undetermined.

Rhea-AI Summary

Biomea Fusion (BMEA) has commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants to purchase common shares.

The company plans to grant the underwriter a 30-day option to buy up to an additional 15% of the total number of shares and pre-funded warrants. All securities in the proposed offering will be sold by Biomea, and completion, size and terms remain subject to market and other conditions. Konik Capital Partners, a division of T.R. Winston & Company, is acting as sole underwriter. The offering is being made under an effective shelf registration statement on Form S-3 filed August 5, 2025 and declared effective August 15, 2025.

News Explained

Potential dilution is directionally unfavorable, but the unpriced offering’s size leaves both dilution and added liquidity unquantified.

Biomea has commenced, but not completed, an underwritten offering in which it would sell common stock and pre-funded warrants, bringing gross proceeds to the company while potentially increasing the share count and reducing existing holders’ ownership percentage.

A pre-funded warrant has a nominal exercise price and converts to shares when exercised; additional shares reduce an existing holder’s percentage ownership absent offsetting changes.

At June 30, 2026, the company reported $34,824,000 of cash, which equals 316 days of the last reported operating cash use at that rate.

Sources and calculations

• Biomea Fusion Announces Proposed Public Offering of Securities (2026-09-22)
• Dilution (2026-07-17)
• Pre-funded warrant (2026-07-17)
• Underwritten offering (2026-07-17)
• Biomea Fusion second-quarter 2026 fundamentals (2026Q2)

• Available liquidity against the last reported quarterly operating outflow, in days at that rate $34,824,000 / ($10,028,000 / 91) = 316 days

Argus 15 min delay

-21.18% vs previous close $1.34 last price 0.9x rel. volume Open Argus

Details

Market reaction after public offering of securities: BMEA -21.18%

$1.33 $1.78 Day Range

$97.13M Market Cap

Following this news, BMEA has declined 21.18%, reflecting a significant negative market reaction. Our momentum scanner has triggered 16 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $1.34.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The platform lists an active S-3 shelf dated Aug. 5, 2025 with two recorded 424B5 usages; this propo...

Analysis

The platform lists an active S-3 shelf dated Aug. 5, 2025 with two recorded 424B5 usages; this proposed offering provided no size, price, or final terms.

Key Figures

Underwriter option period: 30 days Additional securities option: 15% Shelf registration form: Form S-3

Underwriter option period

30 days

Proposed public offering

Additional securities option

15%

Up to additional shares and pre-funded warrants

Shelf registration form

Form S-3

Proposed public offering

Previous Offering Reports

4 past events · Latest: Oct 07

Same Type 4 events

1. Oct 07

   Public offering pricing

   24h Move

   -30.9%

   Priced common stock and pre-funded warrant offering with accompanying warrants

2. Oct 06

   Proposed public offering

   24h Move

   -30.9%

   Announced underwritten offering with 15% overallotment option and undisclosed terms

3. Jun 17

   Public offering pricing

   24h Move

   -34.1%

   Priced shares, pre-funded warrants, and accompanying warrants for gross proceeds

4. Jun 17

   Proposed public offering

   24h Move

   -34.1%

   Announced proposed offering with 15% overallotment option and terms subject to conditions

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pre-funded warrants, underwritten public offering, shelf registration statement, form s-3

4 terms

pre-funded warrants financial

"pre-funded warrants to purchase shares of its common stock"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten public offering financial

"commenced an underwritten public offering of shares of its common stock"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"pursuant to an effective shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"an effective shelf registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Biomea intends to grant the underwriter a 30-day option to purchase up to an additional fifteen percent (15%) of the total number of shares of common stock and pre-funded warrants in the proposed offering. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering are to be sold by Biomea.

The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Konik Capital Partners, LLC, a division of T.R. Winston & Company, is acting as the sole underwriter for the proposed offering.

The proposed offering is being made by Biomea pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289262), filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 5, 2025 and declared effective on August 15, 2025. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and may also be obtained, when available, from: Konik Capital Partners by mail at Attn: 7 World Trade Center, 46^th Floor, New York, NY 10007, or by email at capmarkets@konikcapitalpartners.com or by accessing the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Biomea Fusion

Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Biomea’s beliefs and expectations regarding the proposed offering; uncertainties related to market conditions and statements regarding timing, size and expected proceeds of the proposed offering, and Biomea’s research, development and regulatory plans, the progress of ongoing and upcoming clinical trials and the timing of such events. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to completion of the proposed public offering on the anticipated terms, or at all, market conditions and statements regarding the timing, size and expected gross proceeds of the proposed offering, the grant to the underwriters of the option to purchase additional shares and Biomea’s ability to complete the proposed offering. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Biomea’s most recent annual report on Form 10-K filed on March 24, 2026 and subsequent quarterly reports on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Biomea’s other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the proposed offering to be filed with the SEC. Any forward-looking statements contained in this press release represent Biomea’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Biomea explicitly disclaims any obligation to update any forward-looking statements, except as required by law.

Contact:

Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
IR@biomeafusion.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What additional purchase option is being granted to the underwriter in Biomea Fusion's offering?

Biomea intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of common stock and pre-funded warrants included in the proposed offering.

Who is acting as sole underwriter for Biomea Fusion's proposed public offering?

Konik Capital Partners, LLC, a division of T.R. Winston & Company, is acting as the sole underwriter for the proposed offering.

Under which SEC registration statement is Biomea Fusion conducting this offering?

The proposed offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289262), filed with the SEC on August 5, 2025 and declared effective on August 15, 2025.

How can investors obtain the preliminary prospectus supplement and prospectus for Biomea Fusion's offering?

A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and, when available, may be obtained from Konik Capital Partners by mail at Attn: 7 World Trade Center, 46th Floor, New York, NY 10007, by email at capmarkets@konikcapitalpartners.com, or by accessing the SEC’s website at www.sec.gov.